Nxera Pharma Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	29,615	28,835	12,766	15,569	17,712
Revenue Growth (YoY)	2.71%	125.87%	-18.00%	-12.10%	100.32%
Cost of Revenue	8,198	7,616	3,102	926	933
Gross Profit	21,417	21,219	9,664	14,643	16,779
Selling, General & Admin	11,773	12,924	8,167	3,535	3,138
Research & Development	14,466	11,816	10,075	7,454	5,931
Other Operating Expenses	-5	12	23	-	-2
Operating Expenses	29,686	27,843	20,063	11,831	9,869
Operating Income	-8,269	-6,624	-10,399	2,812	6,910
Interest Expense	-845	-769	-787	-673	-518
Interest & Investment Income	971	1,478	1,225	236	4
Earnings From Equity Investments	-	-	-	-429	50
Currency Exchange Gain (Loss)	16	27	-329	313	22
Other Non Operating Income (Expenses)	-5,015	1,288	-282	696	-3,105
EBT Excluding Unusual Items	-13,142	-4,600	-10,572	2,955	3,363
Merger & Restructuring Charges	-636	-	-	-	-
Gain (Loss) on Sale of Investments	-	1	-46	-1,877	208
Gain (Loss) on Sale of Assets	-12	-63	-62	-	-
Asset Writedown	-1,160	-	-	-	-3,138
Pretax Income	-14,950	-4,662	-10,680	1,078	433
Income Tax Expense	-2,420	176	-3,487	696	-584
Earnings From Continuing Operations	-12,530	-4,838	-7,193	382	1,017
Net Income	-12,530	-4,838	-7,193	382	1,017
Net Income to Common	-12,530	-4,838	-7,193	382	1,017
Net Income Growth	-	-	-	-62.44%	-31.24%
Shares Outstanding (Basic)	90	90	83	82	81
Shares Outstanding (Diluted)	90	90	83	83	82
Shares Change (YoY)	0.61%	8.74%	-0.09%	0.71%	3.16%
EPS (Basic)	-138.80	-53.92	-87.17	4.67	12.53
EPS (Diluted)	-138.80	-53.92	-87.18	4.63	12.40
EPS Growth	-	-	-	-62.66%	-33.30%
Free Cash Flow	-3,116	-8,244	-6,077	9,675	6,902
Free Cash Flow Per Share	-34.52	-91.87	-73.65	117.14	84.17
Gross Margin	72.32%	73.59%	75.70%	94.05%	94.73%
Operating Margin	-27.92%	-22.97%	-81.46%	18.06%	39.01%
Profit Margin	-42.31%	-16.78%	-56.34%	2.45%	5.74%
Free Cash Flow Margin	-10.52%	-28.59%	-47.60%	62.14%	38.97%
EBITDA	-3,903	-2,640	-7,921	4,157	8,188
EBITDA Margin	-13.18%	-9.16%	-62.05%	26.70%	46.23%
D&A For EBITDA	4,366	3,984	2,478	1,345	1,278
EBIT	-8,269	-6,624	-10,399	2,812	6,910
EBIT Margin	-27.92%	-22.97%	-81.46%	18.06%	39.01%
Effective Tax Rate	-	-	-	64.56%	-
Advertising Expenses	384	2,238	-	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.